ATE413399T1 - Morpholinyl-harnstoff-derivative fuer die behandlung von krankheiten verbunden mit entzuendlichen prozessen - Google Patents

Morpholinyl-harnstoff-derivative fuer die behandlung von krankheiten verbunden mit entzuendlichen prozessen

Info

Publication number
ATE413399T1
ATE413399T1 AT03745294T AT03745294T ATE413399T1 AT E413399 T1 ATE413399 T1 AT E413399T1 AT 03745294 T AT03745294 T AT 03745294T AT 03745294 T AT03745294 T AT 03745294T AT E413399 T1 ATE413399 T1 AT E413399T1
Authority
AT
Austria
Prior art keywords
morpholinyl
treatment
diseases associated
urea derivatives
inflammatory processes
Prior art date
Application number
AT03745294T
Other languages
German (de)
English (en)
Inventor
Rachael Ann Ancliff
Caroline Mary Cook
Colin David Eldred
Paul Martin Gore
Lee Andrew Harrison
Martin Alistair Hayes
Simon Teanby Hodgson
Duncan Bruce Judd
Suzanne Elaine Keeling
Xiao Qing Lewell
Gail Mills
Graeme Michael Robertson
Stephen Swanson
Andrew John Walker
Mark Wilkinson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0207434A external-priority patent/GB0207434D0/en
Priority claimed from GB0301608A external-priority patent/GB0301608D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE413399T1 publication Critical patent/ATE413399T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT03745294T 2002-03-28 2003-03-27 Morpholinyl-harnstoff-derivative fuer die behandlung von krankheiten verbunden mit entzuendlichen prozessen ATE413399T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0207434A GB0207434D0 (en) 2002-03-28 2002-03-28 Novel compounds
GB0301608A GB0301608D0 (en) 2003-01-24 2003-01-24 Novel compounds

Publications (1)

Publication Number Publication Date
ATE413399T1 true ATE413399T1 (de) 2008-11-15

Family

ID=28676494

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03745294T ATE413399T1 (de) 2002-03-28 2003-03-27 Morpholinyl-harnstoff-derivative fuer die behandlung von krankheiten verbunden mit entzuendlichen prozessen

Country Status (23)

Country Link
US (1) US7622464B2 (enExample)
EP (1) EP1487828B1 (enExample)
JP (1) JP4465195B2 (enExample)
KR (1) KR20040093488A (enExample)
CN (1) CN1656092A (enExample)
AR (1) AR040403A1 (enExample)
AT (1) ATE413399T1 (enExample)
AU (1) AU2003226757A1 (enExample)
BR (1) BR0308780A (enExample)
CA (1) CA2480106A1 (enExample)
CY (1) CY1108652T1 (enExample)
DE (1) DE60324535D1 (enExample)
DK (1) DK1487828T3 (enExample)
ES (1) ES2315519T3 (enExample)
IL (1) IL164047A0 (enExample)
IS (1) IS7444A (enExample)
MX (1) MXPA04009459A (enExample)
NO (1) NO20044448L (enExample)
PT (1) PT1487828E (enExample)
RU (1) RU2004127928A (enExample)
SI (1) SI1487828T1 (enExample)
TW (1) TW200400035A (enExample)
WO (1) WO2003082861A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050100615A (ko) 2003-01-14 2005-10-19 싸이토키네틱스, 인코포레이티드 화합물, 조성물 및 방법
WO2004089296A2 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
CA2559665A1 (en) 2004-03-16 2005-09-29 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
NZ552404A (en) 2004-06-17 2010-04-30 Cytokinetics Inc Compounds, compositions and methods
EP2289560B1 (en) * 2004-07-08 2015-04-22 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
JP4970946B2 (ja) 2004-09-08 2012-07-11 田辺三菱製薬株式会社 モルホリン化合物
NZ554555A (en) 2004-10-20 2011-09-30 Univ California Cyclohexyl-urea derivatives as improved inhibitors for the soluble epoxide hydrolase
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
EP1959960B1 (en) 2005-12-15 2013-04-10 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
WO2007078815A2 (en) 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2007078839A2 (en) 2005-12-19 2007-07-12 Cytokinetics, Inc. Compounds, compositions and methods
AR059826A1 (es) 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
WO2009029632A1 (en) 2007-08-27 2009-03-05 Helicon Therapeutics, Inc. Therapeutic isoxazole compounds
WO2012054093A2 (en) 2010-01-29 2012-04-26 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase
RU2512293C1 (ru) * 2012-12-13 2014-04-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Ярославский государственный технический университет" Способ получения этил 1,2,4-оксадиазол-5-карбоксилатов
CN107362362B (zh) * 2017-07-20 2019-01-01 复旦大学 Sirt1抑制剂在预防和治疗放射引起的肠道疾病中的应用
EP4178948A2 (en) * 2020-07-29 2023-05-17 Universidade de Santiago de Compostela Functionalized isonitriles and products, preparation and uses thereof
WO2022031735A1 (en) * 2020-08-03 2022-02-10 Global Blood Therapeutics, Inc. Urea derivatives as pyruvate kinase activators
CN119330881A (zh) * 2024-09-06 2025-01-21 苏州汉德创宏生化科技有限公司 一种3-氨甲基-1-h吡唑的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851526A (en) 1987-09-04 1989-07-25 Schering A.G. 1-(4-Substituted phenyl)-1H-imidazoles compounds
JP3087763B2 (ja) 1990-11-30 2000-09-11 三井化学株式会社 新規な複素環式化合物およびそれを含有する医薬組成物
US5219856A (en) 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
WO1995032196A1 (en) 1994-05-19 1995-11-30 Merck Sharp & Dohme Limited Piperazine, piperidine and tetrahydropyridine derivatives of indol-3-ylalkyl as 5-ht1d-alpha agonists
EP0772611A1 (de) 1994-07-20 1997-05-14 Byk Gulden Lomberg Chemische Fabrik GmbH Piperazinothiopyridine zur bekämpfung von helicobacter-bakterien
US5654316A (en) 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
JP3531169B2 (ja) 1996-06-11 2004-05-24 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US6207665B1 (en) 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
IT1293807B1 (it) 1997-08-01 1999-03-10 Recordati Chem Pharm Derivati 1- (n-fenilaminoalchil) piperazinici sostituiti alla posizione 2 dell'anello fenilico
US6031097A (en) 1997-10-27 2000-02-29 Neurogen Corporation 1-(N-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligands
AU1122399A (en) 1997-10-27 1999-05-17 Neurogen Corporation Novel 1-(n'-(arylalkylaminoalkyl))aminoisoindoles; a new class of dopamine receptor subtype specific ligands
CN1325397A (zh) 1998-09-30 2001-12-05 纽罗根公司 2-哌嗪烷基氨基苯并吡咯衍生物∶多巴胺受体亚型特异配体
CZ20031195A3 (cs) 2000-09-29 2003-09-17 Glaxo Group Limited Morfolinacetamidové deriváty
ES2275729T3 (es) 2000-09-29 2007-06-16 Glaxo Group Limited Compuestos utiles en el tratamiento de enfermedades inflamatorias.

Also Published As

Publication number Publication date
WO2003082861A2 (en) 2003-10-09
CY1108652T1 (el) 2014-08-13
EP1487828B1 (en) 2008-11-05
RU2004127928A (ru) 2005-06-27
CN1656092A (zh) 2005-08-17
IL164047A0 (en) 2005-12-18
WO2003082861A3 (en) 2004-03-11
US20060063765A1 (en) 2006-03-23
MXPA04009459A (es) 2005-01-25
ES2315519T3 (es) 2009-04-01
CA2480106A1 (en) 2003-10-09
EP1487828A2 (en) 2004-12-22
DK1487828T3 (da) 2009-02-02
SI1487828T1 (sl) 2009-04-30
AR040403A1 (es) 2005-04-06
IS7444A (is) 2004-09-13
PT1487828E (pt) 2009-01-06
TW200400035A (en) 2004-01-01
BR0308780A (pt) 2004-12-28
DE60324535D1 (de) 2008-12-18
JP2005526815A (ja) 2005-09-08
KR20040093488A (ko) 2004-11-05
US7622464B2 (en) 2009-11-24
AU2003226757A1 (en) 2003-10-13
NO20044448L (no) 2004-10-26
JP4465195B2 (ja) 2010-05-19

Similar Documents

Publication Publication Date Title
ATE413399T1 (de) Morpholinyl-harnstoff-derivative fuer die behandlung von krankheiten verbunden mit entzuendlichen prozessen
ATE374196T1 (de) Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen
DE60329123D1 (de) Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
DE60325498D1 (de) 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen
DE60325209D1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
NL1026329A1 (nl) 2-Amino-pyridinederivaten toepasbaar voor de behandeling van ziekten.
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
NL1025067A1 (nl) Pyrimidinederivaten voor de behandeling van abnormale celgroei.
NL1025071A1 (nl) Verbindingen voor de behandeling van abnormale celgroei.
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
DE60108754D1 (de) Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum
EP1513403A4 (en) USE OF CARDIOTONIC GLUCOSIDES FOR THE TREATMENT OF MUCOVICIDOSIS AND OTHER IL-8 DEPENDENT DISORDERS
ATE345331T1 (de) Verbindungen verwendbar für die behandlung von entzündungskrankheiten
DE60233414D1 (de) Kombinationen für die behandlung entzündlicher erkrankungen
NL1026327A1 (nl) 2-Amino-pyridinederivaten toepasbaar voor de behandeling van ziekten.
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
NO20041882L (no) Fremgangsmater for behandling av okulare neovaskulaere sykdommer.
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
ATE540949T1 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
DE60239558D1 (de) Kombinationen für die behandlung von immun-entzündlichen erkrankungen
ATE424386T1 (de) Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
IL163951A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1487828

Country of ref document: EP